MedPath

Effect of YiqiHuoxueHuatanTongluo formula on restenosis after vertebral artery stenting: A multicenter randomized control trial

Phase 1
Conditions
ischemic cerebrovascular disease
Registration Number
ITMCTR2200006423
Lead Sponsor
China Academy of Chinese Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1 Patients undergoing stent therapy within 14 days because of symptomatic severe vertebral artery stenosis (=70% stenosis as confirmed by DSA) had postoperative residual stenosis <20%, without serious perioperative complications
2 Patients with qi deficiency and blood stasis and phlegm
3 Age is 30-80 years, with no pregnancy planner within 6 months
4 Patients and/or family members signed the informed consent

Exclusion Criteria

1 Patients with severe heart, liver and kidney diseases, coagulation dysfunction and malignant tumors
2 People with a history of allergy or serious adverse reactions to the test drug and its accessories
3 Patients with gastrointestinal ulcer cannot be tolerated with double antiplatelet therapy
4 Pregnancy, breastfeeding women or pregnancy plan recently
5 Unable to take the medicine according to the prescribed dose and course of treatment
6 Use of other TCM for the treatment of cerebrovascular diseases
7 Patients who have participated in other drug clinical trials within 3 months
8 Other circumstances not unsuitable to participate in this trial by the investigator

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
TCM syndrome score;MMSE score;NIHSS score;ADL score;late lumen loss;Cerebral ischemic event;restenosis;thrombelastogram;SSQOL score;
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath